An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A set of reviews and summaries has come out about GHK-Cu, a small peptide that's been discussed as a possible therapy for things like skin aging, wound healing, and inflammation. The news is basically a roundup: researchers and a company called PlexusDx are collecting and explaining the clinical evidence and biomarker data around GHK-Cu to help people understand what the science actually says. GHK-Cu is a tiny piece of protein (a peptide) that naturally occurs in the body and binds copper. In plain terms, think of it like a short molecular tag that can interact with cells and metals. People interested in it say it can signal cells to repair tissue, boost collagen in skin, and reduce inflammation. It's not a drug like a pill or injection by default—it's a molecule studied in labs and, in some cases, in creams or experimental treatments. What the reviews actually show is mixed and limited. Some small human studies and more numerous lab (cell) and animal studies report effects such as improved wound healing, changes in skin biomarkers linked to youthful appearance, or modest anti-inflammatory signals. But the human data are few, often small, and not always randomized or placebo-controlled. Biomarker changes (like levels of certain proteins or gene activity) are easier to measure than real-world outcomes, and the reviews often emphasize molecular signals rather than large, convincing clinical improvements in people. Why this matters is practical: GHK-Cu is already being talked about in skincare and peptide hobbyist communities. If you care about wrinkle reduction, scar healing, or new anti-aging products, these reviews help separate preliminary biological plausibility from proven treatments. For scientists and clinicians, collecting biomarker data helps decide whether larger, more rigorous trials are worth doing. For consumers, it frames expectations: there’s lab support, but not yet strong, large-scale proof that it will do dramatic things in everyday use. There are important caveats and risks. The safety profile in small studies appears acceptable, but comprehensive, long-term safety data in humans are limited. Dosage, formulation (cream vs. injection), purity, and product quality vary a lot in the unregulated market for peptides. People who are pregnant, breastfeeding, or have serious medical conditions should be cautious and consult a clinician. Also, biomarker improvements don’t always translate to meaningful clinical benefits, and regulatory bodies have not broadly approved GHK-Cu as a proven therapeutic. Bottom line: GHK-Cu shows promising biology and some small human data, but it’s early—interesting, not yet definitive—so be cautious about hype and seek medical advice before experimenting.
Source: PlexusDx